Glycomimetics Inc., of Gaithersburg, Md., said it highlighted its glycomimetic drug candidate, E-selectin antagonist GMI-1271, during an oral presentation and poster session. GMI-1271 is currently in preclinical studies for blood cancers and other cancers that are associated with elevated risk of metastasis and thrombosis.